Creative Biolabs Eyes Llama Antibodies Against SARS-CoV-2 Variants

May 19 10:46 2021
As a long-established life science company focusing on antibody discovery and production, Creative Biolabs instantly notices the reported effect of single-domain antibodies (sdAbs) from llamas, alpacas, and yeast against SARS-CoV-2 variants and buckles down to comprehensive sdAb development solutions.

New York, USA – May 18, 2021 – The news covering single-domain antibodies against COVID-19 has been in vogue recently as new studies in Australia have found sdAbs of llamas, alpacas, and camels a promising alternative to help combat SARS-CoV-2 variants and transmission. Inspired by this important medicinal option, Creative Biolabs spares great energy and resources to support research projects on sdAbs and integrates its surface display platform and DNA immunization strategy into the profiles to offer comprehensive solutions.

sdAbs isolated from camelid animals are single variable domain on a heavy chain (VHH) antibodies, which can selectively bind to a specific antigen. The properties of small size, high stability, and outgoing solubility of sdAbs have attracted researchers and scientists to further investigate possible applications, including a therapeutic or prophylactic treatment against COVID-19.

Creative Biolabs has long engaged in the field of novel sdAb development and accomplished numerous challenging sdAb development projects. Based on years of experience, the scientists at Creative Biolabs have collected comprehensive solutions in the whole process of sdAb production and manufacturing, for example, llama antibody production, which may be used to fight SARS-CoV-2 variants. The solutions include complete pathways to achieve the project goals of researchers, from the target identification to the final sdAb production.

Target-specific sdAb Discovery

The development starts from target identification, antigen design, and preparation, in which Creative Biolabs leverages a series of high-quality in-house sdAb libraries originated from camels, llamas as well as humans. Then, sdAbs are generated from different host animals with various immunization strategies, such as DNA immunization, whole cell immunization, and multiple site immunization.

A wide range of sdAb services are available, like immune library based sdAb discovery, B-cell sorting based sdAb discovery, and target-specific polyclonal antibody discovery of polyclonal camelid IgG, polyclonal heavy chain antibody, and polyclonal sdAb.


Supported by advanced tools, technology, and approaches, Creative Biolabs provides a series of characterization solutions, including functional sdAb screening, sdAb affinity measurement, and sdAb stability evaluation, to further analyze and screen sdAb candidates with desired functions.


Multivalent sdAbs and customized sdAb conjugations with increased affinity against the target of interest can also be developed in the procedures of target-specific sdAb development.


Experts at Creative Biolabs can generate the most suitable format of single-domain antibodies taking advantage of different constructs, expression systems, fusion tags, and labels, supporting high-quality and scale-up sdAb production under GLP and GMP standards.

About Creative Biolabs

Creative Biolabs is a leading antibody service provider equipped with advanced platforms, powerful technologies, and extensive experiences. It has long been devoted to antibody development and applications, meanwhile, takes the responsibility to assistant any study on potential therapeutics against COVID-19.

Find more sdAb services, resources, and products at

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States